-

Julie Dehaene-Puype and Erik Nordkamp appointed as new regional Commercial Officers for Mundipharma

CAMBRIDGE, England--(BUSINESS WIRE)--FOR MEDICAL BUSINESS/INDUSTRY TRADE MEDIA ONLY

The Mundipharma network of independently associated companies today announced two new appointments to their Executive Committee – Julie Dehaene-Puype as Chief Commercial Officer, Europe and Erik Nordkamp as Chief Commercial Officer, LAM (Latin America, Asia Pacific, Middle East-Africa) – both reporting into Marc Princen, Chief Executive Officer.

Speaking of the appointments, Marc Princen commented, “I am delighted to welcome Julie and Erik as highly experienced pharmaceutical leaders to complete our global organisation. They join us during a pivotal year for some of our pipeline assets as we continue to increase access to healthcare for many of the world’s most challenging diseases.”

Julie Dehaene-Puype is joining Mundipharma with over 20 years’ industry experience from Takeda, Merck and Schering Plough, where she has held strategic and operational roles at country, regional and global level across the US, Europe and Canada. Julie joins Mundipharma from Takeda where she was recently General Manager of France. Her role at Mundipharma will see her cover the Europe region.

“I am thrilled to be joining the Mundipharma global organisation,” Julie commented. “I am looking forward to utilising my experience to build on the inclusive culture that enables our people to work together, think differently and to transform the lives of patients all around the world.”

Erik Nordkamp is a pharmaceutical professional with over 20 years’ experience in strategy, general management and marketing from Pfizer and Eli Lilly, with regional roles that have spanned Europe, Canada and Australia. Most recently Erik was Regional VP & Cluster Lead Europe/Australia/NZ Upjohn Division at Pfizer. His new role at Mundipharma will see him cover the LAM region, which encompasses Latin America, Asia Pacific, Middle East-Africa.

Commenting on his appointment, Erik said: “This is an exciting time for Mundipharma as we expand our global network and I feel proud to be taking responsibility for the key LAM region. Think global, act local is how I envision we can deliver lasting change for patients.”

-Ends-

Notes to editors:

About the Mundipharma network

Mundipharma is a global (ex-US) network of independent associated companies with a presence across Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East.

As a dynamic, forward-looking organisation we are dedicated to bringing innovative treatments to patients in the areas of Pain & Supportive Care and Consumer Healthcare as well as other severe and debilitating disease areas.

Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything we do.

For more information visit www.mundipharma.com

Contacts

Helen Rae
helenrae@makarahealth.com
T: +44 (0) 23 81 247 327

Rob Gallo
rob.gallo@mundipharma.com
T: +44 (0) 7773 009578

Mundipharma


Release Versions

Contacts

Helen Rae
helenrae@makarahealth.com
T: +44 (0) 23 81 247 327

Rob Gallo
rob.gallo@mundipharma.com
T: +44 (0) 7773 009578

More News From Mundipharma

Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)

CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma today announced completion of patient enrolment for the ongoing, global Phase III ReSPECT trial evaluating REZZAYO® (rezafungin). The ReSPECT trial is a global, randomised, double-blind, controlled, pivotal Phase 3 trial of rezafungin versus the standard antimicrobial regimen to prevent invasive fungal disease due to Candida, Aspergillus and Pneumocystis in subjects undergoing allogeneic blood and marrow transplantation. “Completing patient enrol...

New global guideline published on managing fungal infections caused by Candida

CAMBRIDGE, England--(BUSINESS WIRE)--A new global guideline for the diagnosis and treatment of Candida infections was recently published in Lancet Infectious Diseases1. This guideline sets out new standards for managing fungal infections, which affect millions of people worldwide every year. The global guideline was developed by a team of more than 100 experts spanning 35 countries and led by Professor Dr. Oliver A. Cornely and Dr. Rosanne Sprute from University Hospital Cologne. One year follo...

Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area

CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafungin is a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3...
Back to Newsroom